Application Detail
Status
OpenDescription of Medical Service
Tisagenlecleucel is an autologous, murine anti-CD19 chimeric antigen receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.Description of Medical Condition
Acute lymphoblastic leukaemia (ALL) is the malignant proliferation of lymphoid progenitor cells in the bone marrow.Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin lymphoma (NHL).
Reason for Application
New non-MBS itemMedical Service Type
Hybrid health technologyPrevious Application Number
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 842 KB)Application Form (Word 498 KB)
PICO Confirmation
PICO Confirmation (PDF 1458 KB)PICO Confirmation (Word 743 KB)
Assessment Report
-Public Summary Document
Public Summary Document (PDF 1116 KB)Public Summary Document (Word 126 KB)
Meetings for this Application
PASC
12-13 April 2018ESC
5 October 2018MSAC
22-23 November 201828-29 March 2019
9 April 2019